“By necessity, COVID-19 has pushed the cancer clinical trial community out of its comfort zone to rapidly deploy remote assessments and digital health technology, [prompting] unprecedented collaboration to explore the use of real-world data. We cannot lose this opportunity to learn and advance our knowledge of the strengths and limitations of decentralized trials and real-world […]

Oncology segment accounted for the largest share of the RWE solutions market in 2017 The rising focus on end-to-end RWE services and growth within emerging markets are expected to provide further business opportunities for players operating in the RWE market Click here to learn more About SVMPharma SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence […]

The analysis captures the first survival data from the National Cancer Database (NCDB) since the FDA’s 2015 approval of ipilimumab (Yervoy) following curative intent surgery in stage III patients. Survival data were available for the 4,094 patients diagnosed in 2015, of which 1,014 were treated with immunotherapy. At 1 year, 93% of patients that received surgery plus […]

NICE recommendations determine access to tyrosine kinase inhibitors (TKIs) Median duration of treatment by line also decreased as more TKIs were recommended by NICE Promisingly, the study also found that the proportion of patients in major molecular response increased by line Click here to read the abstract in the British Journal of Haematology (abstract number: […]

“A truly high-value drug is the one that costs the least and has the most benefit for our patients” “What we need is more research focusing on value-based pricing, rigorous post-approval follow-up for efficacy and toxicity, and use of real world evidence in the creation of standardized treatment pathways.” Devika Das, MBBS, Clinical Assistant Professor […]